Clinical Edge Journal Scan

Factors affecting clinical response to fecal microbial transplantation in PsA


 

Key clinical point: Intestinal permeability as well as fecal and plasma metabolomic profiles significantly affected the clinical response to fecal microbial transplantation (FMT) or sham transplantation in patients having peripheral moderate-to-high psoriatic arthritis (PsA) despite receiving methotrexate for ≥3 months.

Major finding: Lactulose-to-mannitol ratio was higher at week 26 (0.027 vs 0.012; P = .013), indicating greater small intestinal permeability; moreover, fecal ( P < .0001) and plasma ( P = .005) metabolomic profiles differed in patients who needed vs did not need treatment intensification after undergoing an FMT or sham transplantation.

Study details: This exploratory study of the FLORA trial included 31 patients who had peripheral moderate-to-high PsA despite ≥3 months of methotrexate treatment and were randomly assigned to undergo either gastroscopic-guided single-donor FMT (n = 15) or sham transplantation (n = 16).

Disclosures: This study was supported by Sygeforsikringen “danmark” and other sources. Three authors declared receiving financial support, grants, or lectureship awards from various sources.

Source: Kragsnaes MS et al. Small intestinal permeability and metabolomic profiles in feces and plasma associate with clinical response in patients with active psoriatic arthritis participating in a fecal microbiota transplantation trial: Exploratory findings from the FLORA trial. ACR Open Rheumatol. 2023 (Sep 22). doi: 10.1002/acr2.11604

Recommended Reading

FDA approves topical roflumilast for psoriasis in children aged 6-11
MDedge Rheumatology
Choosing which biologic to prescribe for psoriasis
MDedge Rheumatology
Intravenous formulation of secukinumab gets FDA approval
MDedge Rheumatology
Pediatric psoriasis: Black children, males more likely to have palmoplantar subtype, study finds
MDedge Rheumatology
Roflumilast side effect benefits patients with psoriasis and overweight/obesity
MDedge Rheumatology
Approximately 20% of U.S. adults are diagnosed with arthritis
MDedge Rheumatology
Pilot study: High-dose IL-23 inhibition shows promise for psoriasis remission in some patients
MDedge Rheumatology
FDA approves bimekizumab for moderate to severe plaque psoriasis in adults
MDedge Rheumatology
Bimekizumab offers sustained clinical response in bDMARD-naive PsA patients
MDedge Rheumatology
IL-17 and IL-23(p19) inhibitors as effective as TNF inhibitors in PsA
MDedge Rheumatology